financingADC Therapeutics buys time for Zynlonta with $86.6M financingSwiss biotech ADC Therapeutics has secured an $86.6 million (€77.5 million) financing agreement alongside debt and royalty deal amendments that extend its expected cash runway into 2029 and remove … more ➔
clinical dataAnother bad day at Zealand: Roche-partnered drug disappoints on blood sugarZealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood sugar … more ➔
licensingRoche taps Chinese biotech Defand in reported $1B dealRoche has partnered with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases, in a research and licensing agreement reportedly worth close to $1 billion … more ➔
clinical dataArgenx halts Phase 3 Sjögren’s trial, sending shares tumblingArgenx is stopping its Phase 3 UNITY trial of efgartigimod in Sjögren’s disease after an interim analysis showed the study could not meet its primary endpoint. Shares fell about 18% in Euronext Brussels … more ➔
artificial intelligenceRivercell raises $25M to build an AI virtual cellParis-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI models that predict how human cells respond to drugs and genetic changes … more ➔
SurveyReport: Europe’s biotech leaders see recovery, but investors remain the obstacleExclusive European data from BIO-Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among … more ➔
Venture CapitalForbion raises record-breaking €2.3B to back 30 biotechsDutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, setting a fundraising record for the firm. more ➔
startupSensible secures $47M to rethink mRNA manufacturingOxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that makes mRNA in living cells, targeting manufacturing costs and unwanted immune … more ➔
fundraisingRougeTx launches with $58M to tackle rare bleeding disorderDutch biotech RougeTx has launched with a $58 million (€52 million) series A to take its lead drug RTX-001 toward first-in-human testing in hereditary hemorrhagic telangiectasia (HHT). The round was … more ➔
lymphomaGenmab and AbbVie’s bispecific antibody halves progression-or-death risk in lymphoma trialGenmab and AbbVie’s bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma … more ➔
